A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

• Drug: PF-06700841
  
  a single oral dose of 200 mg PF-06700841
• Drug: Placebo
  
  Placebo matching PF-06700841
• Drug: moxifloxacin
  
  a single oral dose of 400 mg moxifloxacin

• Experimental: Seq 1
  
  PF-06700841-> placebo-> moxifloxacin
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin
• Experimental: Seq 2
  
  PF-06700841->moxifloxacin->placebo
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin
• Experimental: Seq 3
  
  Placebo->PF-06700841->moxifloxacin
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin
• Experimental: Seq 4
  
  Placebo->moxifloxacin->PF-06700841
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin
• Experimental: Seq 5
  
  Moxifloxacin->PF-06700841->placebo
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin
• Experimental: Seq 6
  
  Moxifloxacin->placebo->PF-06700841
  Interventions:
  

  • Drug: PF-06700841
  • Drug: Placebo
  • Drug: moxifloxacin

Inclusion Criteria:

• Healthy female subjects of non-childbearing potential and/or male subjects. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including BP and pulse rate measurement, 12-lead ECG, or clinical laboratory tests.
• Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb) at screening.
• Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic (including alcoholic liver disease, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary liver diseases), psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing)
• Self-reported history or risk factors for QT prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia, congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness, family history of sudden death, and family history of long QT syndrome.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product (whichever is longer)
• Subjects with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a trial involving PF-06700841
• History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON- tuberculosis (TB) Gold test
• History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb)
• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing
• Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.